Written and maintained by CASRAI Editorial Board
Last updated
The Biomedical Catalyst is a translational funding programme jointly run by Innovate UK and the Medical Research Council (MRC) — both UKRI constituent organisations — for UK small and medium-sized enterprises (SMEs) developing innovative health and care technologies. It sits at a different point in the funding landscape from a conventional MRC research grant: rather than funding university-led discovery research, it funds commercially-oriented development work carried out by, or in partnership with, an SME. This guide covers what it funds, who’s eligible, how it’s structured, and how it differs from adjacent UKRI schemes administrators are more likely to already know. See CASRAI’s MRC Funding and Innovate UK Smart Grants guides for the two parent schemes this one sits between.
Origin and purpose
The Biomedical Catalyst was established in 2012 to address three linked problems in the UK life sciences sector: accelerating the growth of health and biomedical SMEs, getting innovative healthcare products and services to patients faster, and bridging the funding gap between academically-driven early research and commercially-driven late-stage development — the so-called “valley of death” where a promising discovery is too developed for a standard research grant but too early-stage for private investment. Its joint Innovate UK/MRC structure reflects that dual purpose directly: MRC’s involvement anchors it to genuine biomedical/health-research relevance, while Innovate UK’s involvement anchors it to commercial viability and business growth, rather than either agency funding it alone.
Who administers it, and which application system to use
Biomedical Catalyst competitions are run through Innovate UK, not through the UKRI Funding Service that MRC’s own research grants use. Applications go through the separate Innovation Funding Service (apply-for-innovation-funding.service.gov.uk) — the same platform used for Innovate UK’s other competitions, including Smart Grants and Knowledge Transfer Partnerships. Administrators used to submitting MRC proposals through the UKRI Funding Service should not assume the same account, forms, or costing categories carry over — the two platforms hold no shared account data.
What it funds: current competition structure
Total programme funding is roughly £140 million across the current UK government spending review period, run as recurring competitions rather than a single continuous fund. The live programme groups funding around three tracks by project maturity:
- Accelerator (feasibility). Funding to test market and technology feasibility at an early stage.
- Industry-led R&D. Larger, transformational grants for innovation projects further along in development.
- Investor Partnerships. Public grant funding paired with private investment, designed to de-risk a project for outside investors rather than fund it on public money alone.
This is a narrower structure than the programme originally used: earlier competitions (and some still-referenced GOV.UK guidance from the programme’s first several years) describe a four-stage model — Feasibility, Primer, Early-stage, and Late-stage — corresponding to increasing technical and clinical maturity. Administrators encountering that older four-track terminology in historical guidance or a university’s internal funding-finder notes should check the current live Innovate UK competition listing rather than assume the older stage names still apply; the underlying maturity-staged logic is the same, but the current competition names have changed.
Eligibility
Applicants must be UK-based small or medium-sized enterprises planning to carry out the project work in the UK. Depending on project stage and business size, an applicant can work alone or in collaboration with others — including, in practice, a university research group as a project partner, which is the route through which a university research office is most likely to encounter this scheme, rather than as the lead applicant itself.
How it differs from adjacent UKRI schemes
Three comparisons come up often enough to be worth stating directly:
- Biomedical Catalyst vs. a standard MRC research grant. An MRC research grant funds investigator-led biomedical research at a UK research organisation, assessed on scientific merit within MRC’s remit. The Biomedical Catalyst funds SME-led commercial development, assessed partly on route to market and business viability, not on academic research merit alone.
- Biomedical Catalyst vs. Innovate UK Smart Grants. Smart Grants are open to any sector and any UK registered business; the Biomedical Catalyst is sector-specific to health and life sciences and jointly governed with MRC, giving it health-research-specific assessment criteria that a general Smart Grant panel wouldn’t apply.
- Biomedical Catalyst vs. Knowledge Transfer Partnerships (KTP). A KTP funds a specific collaborative project embedding a graduate between a business and an academic partner over a fixed term; the Biomedical Catalyst funds a company’s own development project directly, with a university (if involved at all) as a project partner rather than a co-applicant employing a KTP associate.
What this means in practice for research administrators
- This is Innovate UK’s application system, not UKRI’s. Route any Biomedical Catalyst-related enquiry to the Innovation Funding Service, not the UKRI Funding Service account a research office may already use for MRC or other council grants.
- A university’s role is usually “project partner,” not “lead applicant.” The SME leads; check what costing/subcontract arrangement applies to the university’s contribution before assuming standard fEC grant terms apply, since this is a business-led competition, not a research-council responsive-mode grant.
- Check the live competition track names before reusing old guidance. Historical “Feasibility/Primer/Early-stage/Late-stage” terminology may not match the current “Accelerator/Industry-led R&D/Investor Partnerships” structure — confirm against the live Innovate UK listing.
- Competitions run recurring rounds, not continuous submission — unlike an applicant-led/responsive-mode research council grant, check current open competition dates on the Innovation Funding Service rather than assuming a rolling deadline.
Frequently asked questions
Who runs the Biomedical Catalyst?
Innovate UK and the Medical Research Council (MRC) jointly — both UKRI constituent organisations. Competitions are administered by Innovate UK through the Innovation Funding Service.
Can a university apply for Biomedical Catalyst funding directly?
No. Eligible direct applicants are UK-based small and medium-sized enterprises. A university research group can be involved as a project partner alongside an SME applicant, but cannot lead the application itself.
Is the Biomedical Catalyst the same as an MRC research grant?
No. An MRC research grant funds investigator-led biomedical research through the UKRI Funding Service, assessed on scientific merit. The Biomedical Catalyst funds SME-led commercial development through the separate Innovation Funding Service, assessed partly on commercial viability.
When was the Biomedical Catalyst established?
2012, to accelerate SME growth, speed up delivery of innovative healthcare products, and bridge the funding gap between early academic research and later-stage commercial development.
How much funding does the Biomedical Catalyst provide?
Roughly £140 million across the current UK government spending review period, distributed through recurring competitions rather than a single continuous pot.
